Related Experiment Video

Updated: Apr 8, 2026

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4
06:56

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4

Published on: March 10, 2018

14.7K

Finding Fusin/CXCR4, the First "2nd Receptor" for HIV Entry

Edward A Berger1

  • 1Molecular Structure Section, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, MD , USA.

Frontiers in Immunology
|June 25, 2015
PubMed
Abstract

No abstract available in PubMed .

Keywords:
CCR5CD4Env glycoproteinT cell linecell fusioncoreceptormacrophagetropism

More Related Videos

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors
16:49

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors

Published on: July 16, 2012

12.1K
A High-throughput Cre-Lox Activated Viral Membrane Fusion Assay to Identify Inhibitors of HIV-1 Viral Membrane Fusion
07:22

A High-throughput Cre-Lox Activated Viral Membrane Fusion Assay to Identify Inhibitors of HIV-1 Viral Membrane Fusion

Published on: August 14, 2018

7.1K

Related Experiment Videos

Last Updated: Apr 8, 2026

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4
06:56

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4

Published on: March 10, 2018

14.7K
Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors
16:49

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors

Published on: July 16, 2012

12.1K
A High-throughput Cre-Lox Activated Viral Membrane Fusion Assay to Identify Inhibitors of HIV-1 Viral Membrane Fusion
07:22

A High-throughput Cre-Lox Activated Viral Membrane Fusion Assay to Identify Inhibitors of HIV-1 Viral Membrane Fusion

Published on: August 14, 2018

7.1K

Related Concept Videos

Receptor-mediated Endocytosis01:20

Receptor-mediated Endocytosis

12.3K
Receptor-mediated endocytosis is when bulk amounts of specific molecules are imported into a cell after binding to cell surface receptors. The molecules bound to these receptors are taken into the cell through inward folding of the cell surface membrane, which is eventually pinched off into a vesicle within the cell. Structural proteins, such as clathrin, coat the budding vesicle.
Clathrin-Mediated Endocytosis of LDL
One well-characterized example of receptor-mediated endocytosis is the...
12.3K
Receptor-mediated Endocytosis01:38

Receptor-mediated Endocytosis

113.6K
Overview
113.6K
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

3.8K
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
3.8K

Articles linked to this work by shared authors, journal, and citation graph.

Development of an anti-CAR antibody response in SIV-infected rhesus macaques treated with CD4-MBL CAR/CXCR5 T cells.

Frontiers in immunology·2022

HIV-Specific CAR T Cells with CD28 or 4-1BB Signaling Domains Are Phenotypically and Functionally Distinct and Effective at Suppressing HIV and Simian Immunodeficiency Virus.

ImmunoHorizons·2022

CAR/CXCR5-T cell immunotherapy is safe and potentially efficacious in promoting sustained remission of SIV infection.

PLoS pathogens·2022

Production and Characterization of SIV-Specific CAR/CXCR5 T Cells.

Methods in molecular biology (Clifton, N.J.)·2021

iTIME.219: An Immortalized KSHV Infected Endothelial Cell Line Inducible by a KSHV-Specific Stimulus to Transition From Latency to Lytic Replication and Infectious Virus Release.

Frontiers in cellular and infection microbiology·2021

An immunotoxin targeting Ebola virus glycoprotein inhibits Ebola virus production from infected cells.

PloS one·2021

OTULIN: a master regulator of linear ubiquitin homeostasis in immune signaling, inflammation, and disease.

Frontiers in immunology·2026

Regulatory T cells in cardiac allograft vasculopathy: from mechanistic insights to clinical tolerance.

Frontiers in immunology·2026

The CD47 signaling axis regulates the formation and vulnerability of atherosclerotic plaques: mechanism analysis and targeting strategies.

Frontiers in immunology·2026

Regulatory T cells in intracerebral hemorrhage: mechanisms of immunomodulation and therapeutic potential.

Frontiers in immunology·2026

Time-resolved multi-omics reveals macrophage-centered immunometabolic remodeling in cutaneous dematiaceous fungal infection.

Frontiers in immunology·2026

Lipoprotein (a) fuels EV71 replication by activating p38 MAPK-autophagy axis.

Frontiers in immunology·2026

Occurrence of Infusion Associated Reactions and Antidrug Antibodies in Enzyme Replacement Therapy for Fabry Disease and the Effect of Preventive Measures.

Journal of inherited metabolic disease·2026

NRAS knockdown reverses monocytic cell state and resensitizes resistant FLT3-AML cells to gilteritinib.

Blood·2026

Amyloid-Related Imaging Abnormalities Summit Special Proceedings: Cardiovascular and Stroke Considerations for β-Amyloid Immunotherapy in Alzheimer Disease.

Journal of the American Heart Association·2026

Inhibiting PIK3C3/VPS34 enhances anti-GD2 immunotherapy in neuroblastoma.

Autophagy·2026

Toward Personalized Theranostics: A Modular PET Platform for Antibody-Based Imaging and Therapy.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

Targeted Degradation of KAT6A: Expanding the Therapeutic Frontier of Epigenetic Drug Discovery.

ACS medicinal chemistry letters·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us